Jazz Pharmaceuticals PLC Form 4 insider transactions

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, reported changes in her beneficial ownership, including shares withheld for tax obligations and an acquisition via an employee stock plan.

Jazz Pharmaceuticals plc CEO Bruce C. Cozadd sold 1,000 ordinary shares for $113.21 each on August 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals plc's Chairman and CEO, Bruce C. Cozadd, reported the sale of 1,000 ordinary shares through a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals plc's Chairman and CEO, Bruce C. Cozadd, reported the sale of 1,000 ordinary shares through a pre-arranged 10b5-1 trading plan in early June, while also acquiring 166 shares via an employee stock purchase plan.

Director Seamus Mulligan reports purchasing Jazz Pharmaceuticals shares through Nerano Pharma Limited in multiple transactions.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold a portion of his ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold 1,500 ordinary shares at $123.75 per share on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals, reported the sale of 2,403 ordinary shares on March 10, 2025.

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, sold 698 ordinary shares to satisfy tax obligations from vesting restricted stock units.

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, reports the sale of ordinary shares to cover tax obligations and other transactions.

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, sold 1,905 ordinary shares to cover tax obligations arising from vesting restricted stock units.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, disposed of 4,088 ordinary shares to satisfy tax obligations arising from vesting restricted stock units.

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals plc, sold 1,149 ordinary shares on March 5, 2025, to satisfy tax obligations arising from vesting restricted stock units.

Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals, sold shares of the company's stock on March 5th and 7th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Renee D Gala, President & COO of Jazz Pharmaceuticals, sold 5,704 ordinary shares on March 5, 2025, to cover tax obligations arising from the vesting of restricted stock units.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, disposed of 22,251 ordinary shares to satisfy tax obligations arising from the vesting of restricted stock units.

Robert Iannone, EVP, G R&D and CMO of Jazz Pharmaceuticals, reports acquisition of restricted stock units.

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, reports the acquisition of ordinary shares through restricted stock units.

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, reports the acquisition of restricted stock units.

Renee D. Gala, President & COO of Jazz Pharmaceuticals, reports the acquisition of restricted stock units under the company's 2011 Equity Incentive Plan.

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals, reports the acquisition of ordinary shares and restricted stock units.

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals, reports the acquisition and disposal of ordinary shares and derivative securities.

Neena Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the sale and acquisition of ordinary shares and restricted stock units.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, reports acquisition of restricted stock units and sale of ordinary shares.

Jazz Pharmaceuticals CEO Bruce Cozadd sold 1,500 ordinary shares at $122.31 per share on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Robert Iannone, EVP, G R&D and CMO of Jazz Pharmaceuticals, reports the acquisition of 7,506 ordinary shares and the disposal of 2,181 shares to cover tax obligations following the vesting of performance share awards.

Jazz Pharmaceuticals CEO Bruce Cozadd acquired 29,559 ordinary shares through the vesting of a performance share award, while 13,840 shares were withheld for tax obligations.

Jazz Pharmaceuticals' President & COO, Renee D Gala, acquired shares through performance award vesting and sold some to cover tax obligations.

Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals, acquired 1,641 ordinary shares following the vesting of performance-based awards.

Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena Patil, acquired shares following the vesting of performance awards and sold shares to cover tax obligations.